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Improved Efficacy of a Dendritic Cell-Based Vaccine against 
a Murine Model of Colon Cancer: The Helper Protein Effect
Purpose
Targeted immunotherapy using dendritic cells (DCs) has been employed in numerous 
investigations aiming at combating neoplasms. We previously showed that copulsing of an
antigen with a helper protein could considerably enhance antigen presenting capacity of ex
vivo–generated DCs. In this study, we attempted to administer an effective treatment in 
a murine model of colon cancer with DCs pulsed with the mixture of a tumor-specific 
gp70-derived peptide (AH1) and a helper protein, ovalbumin (OVA).
Materials and Methods
First, the presence of gp70 in CT26 tumor cells and tumor tissues was verified using 
immunofluorescence and Western blot analyses. Next, DCs were purified from normal mice,
loaded ex vivo with AH1 and OVA (DC-Pep-OVA), and injected into tumor-bearing mice. Tumor
volume, in vitro antigen (Ag)-specific proliferation of splenic cells, and survival rate were
measured to determine the efficacy of DC-Pep-OVA. As the control groups, tumor-bearing
mice were vaccinated with DC-Pep, unpulsed DC, and DCs loaded with a mixture of OVA
and an irrelevant peptide (P15), or were not vaccinated at all.
Results
DC-Pep-OVA showed superior efficacy over other groups, as indicated by smaller tumor 
volume, higher Ag-specific proliferation rate of splenic cells, and prolonged survival.
Conclusion
Overall, in the present study we showed for the first time that DCs copulsed with AH1 (tumor
Ag) and OVA (helper molecule) could be considered as potentially robust weapons for use
in future antitumor immunotherapies. 
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Introduction
For many years, chemotherapy, radiotherapy, and surgery
have been the mainstay treatment for various forms of
human cancer. Despite providing variably effective treat-
ments in many cases, the risk of cancer recurrence due to 
acquired chemoresistance through different mechanisms,
and the significant damage to the surrounding healthy tissue
have remained as major hurdles in cancer therapy [1].
In recent years, many components of the immune system
have been shown to be effective in restriction of tumor
growth and/or tumor elimination, placing immunotherapy
on center stage as a biological approach to cancer therapy. In
the effort to combat cancer, researchers have utilized diverse
strategies, including adoptive transfer of activated T cells and
antigen presenting cells (APCs) [2,3], and development of
monoclonal antibodies (Abs) against tumor antigens (Ags)
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[4]. However, these strategies have not been completely 
successful in control of tumor growth or its eradication.
Tumor cells have the ability to evade the adaptive and innate
immune defense responses through changes in their surface
Ags and synthesis of APC suppressive factors leading to 
inhibition of T-cell responses [5]. 
Dendritic cells (DCs) are among the most potent APCs and
have a superior capacity to recognize, engulf, and process
Ags, be it of foreign origin or mutated host cells, and finally
present them to T cells. Depending on the nature of the Ag,
the maturation state of DCs and their ability to express 
costimulatory and/or inhibitory molecules within their 
microenvironment, DCs play a significant role in modulating
the immune response by selective activation and differenti-
ation towards Th1, Th2, Th17, and/or Treg subsets. This
overall immunomodulatory capacity makes DCs an attrac-
tive candidate for cancer immunotherapy [2].
Significant advances have been made in the development
of DC-based cancer vaccines. In many of these vaccines ex
vivo–generated DCs are loaded with specific tumor Ags (in
the absence of suppressive tumor–associated Ags) and then
put back into the host [2]. Several strategies have been devel-
oped to maximize the efficiency and longevity of Ag presen-
tation by ex vivo DCs, including simultaneous loading of
microbial components with tumor Ags, triggering costimu-
latory molecules and their ligands on the surface of DCs, and
Th1 cytokine gene transfer to DCs [6]. Application of any
given single approach per se does not warrant the optimum
tumor cell killing capacity and combinations of two or more
DC activating strategies are often required [7].
An alternative approach to augment the immunogenicity
of tumor Ags and achieve more powerful DC-based cancer
vaccines is the use of carrier proteins linked to the tumor Ag
[8]. These carrier proteins, also called third-party Ags, boost
the CD4 and CD8 responses against the tumor Ag. Timmer-
man and Levy [9] were the first to demonstrate that loading
DCs with tumor Ags linked to an immunogenic protein (key-
hole limpet hemocyanin, KLH) significantly increased the
antitumor immune response [9]. In another study, they
showed that in tumor-bearing mice immunized with idio-
type protein-loaded DCs, the anti-idiotype immune response
only occurred when the KLH-linked Id protein was used
[10]. Millard et al. [11] also reported that DCs pulsed with
KLH-linked peptide produced a much stronger peptide-
specific immunogenic response compared to the peptide
alone group. They also demonstrated that KLH significantly
increased the antitumor capacity of DC vaccines and their
ability to induce tumor specific cytotoxic T cells through 
activation of T helper lymphocytes [11].
Our laboratory demonstrated that coupling of a helper Ag
with the target tumor Ag increased the efficiency and stabil-
ity of Ag presentation by DCs and elicited more robust 
immunogenic responses against both the target tumor Ag
and the helper Ag [12]. This phenomenon, which we called
a “mutual helper effect,” generates better Ag-specific 
immune responses against both Ags. Other studies demon-
strated that the enhanced tumor-specific Ag presentation
was not limited to the inclusion of KLH alone, and many
other foreign Ags, even less immunogenic ones were capable
of producing powerful DC-based vaccines in normal mice
[13,14]. 
In this work, we attempted to determine whether treat-
ment of a murine model of colon cancer with DCs copulsed
with ovalbumin (OVA) (as the helper Ag) and a gp70-
derived peptide (AH1) could inhibit tumor growth and 
induce a potent Ag-specific immune response.
Materials and Methods
1. Animals
Eight- to 12-week-old BALB/c mice were obtained from
the Pasteur Institute, Iran. Animals were housed and main-
tained under optimal light, temperature, and humidity 
conditions with free access to food and water. All procedures
were approved by the Animal Care Ethical Committee at
Avicenna Research Center.
2. Cell line
CT26 mouse colon carcinoma cells were purchased from
the Pasteur Institute, Iran, and used for this study. These cells
express gp70, a murine endogenous tumor Ag. The AH1
peptide of this Ag has also been identified as a cytotoxic T
lymphocyte (CTL)–epitope capable of inducing tumor 
specific CTL immune responses [13]. CT26 cells were 
routinely maintained in RPMI-1640 medium (Gibco, Karl-
sruhe, Germany) containing 10% (v/v) fetal bovine serum
(FBS; Gibco) and 2 mM L-glutamine (Sigma-Aldrich, St.
Louis, MO) in 25 cm2 and 75 cm2 flasks (SPL, Pocheon,
Korea).
3. Generation of AH1 peptide-specific antibody
Generation of anti-AH1 polyclonal Ab was performed 
according to a method described elsewhere [15]. In brief,
KLH-conjugated AH1 peptide (amino acid sequence, 
SPSYVYHQF) was injected in conjunction with IMMACELL
(Stockholm, Sweden) and Freund adjuvant (Sigma-Aldrich)
into an 8-week-old New Zealand rabbit once per week for 3
consecutive weeks and a booster injection was administered
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1 month later. Blood samples were collected before the 
immunization and 1 week after each injection. Sera were 
separated and stored at –20°C. Specific anti-AH1 polyclonal
Ab was purified using affinity chromatography and its 
purity was checked by sodium dodecyl sulfate polyacry-
lamide gel electrophoresis (SDS-PAGE). The immunoreac-
tivity of the hyperimmune serum and purified Ab against
AH1 peptide was confirmed by enzyme-linked immunosor-
bent assay (ELISA).
4. Immunofluorescence analysis of gp70 expression in
CT26 cells
Expression of gp70 protein in CT26 cells was determined
using the above-mentioned purified anti-AH1 Ab according
to the protocol, which is described elsewhere [16]. Briefly,
cultured CT26 cells were detached by trypsinization,
washed, cytospun onto microscope slides, and fixed with ice
cold acetone. After blocking endogenous biotin (Dako,
Glostrup, Denmark) and the hydrophobic sites (5% normal
sheep serum), purified anti-AH1 Ab (4 µg/mL) was applied
overnight at 4°C. Cells were then sequentially incubated with
biotinylated sheep anti-rabbit IgG (Avicenna Research Insti-
tute, Tehran, Iran) and FITC-conjugated streptavidin
(Biosource, New York, NY). The nuclei were stained with 
7-AAD (Sigma-Aldrich) for 5 minutes. Cells stained with 
primary Ab, which had been adsorbed with immunizing
peptide or pre-immune rabbit IgG, served as the reagent 
negative control. Fluorescent signals were visualized under
an immunofluorescence microscope (BX50, Olympus Optical
Co., Tokyo, Japan).
5. Western blot analysis of gp70 expression in CT26 cells
and tumors
Expression of gp70 protein in CT26 cells and tumors was
determined using the purified anti-AH1 Ab mentioned
above. In brief, CT26 cells and tumor tissues were homoge-
nized on ice for 1 hour in a lysis buffer containing NaCl (100
mM), Na4P2O (20 mM), glycerol (1% v/v), Tris (10 mM; pH
7.4) (all from Gibco), Triton X-100 (2% v/v), EDTA (1 mM),
NaF (1 mM), and SDS (0/1 % w/v) (all from USB, Cleveland,
OH). Subsequently, the lysates were centrifuged, and the 
supernatants were collected, and stored at –20°C until analy-
sis. Total protein concentration was determined using a BCA
kit (Pierce, Rockford, IL) according to the manufacturer's 
instructions. Lysates were subjected to SDS-PAGE elec-
trophoresis followed by protein transfer onto the PVDF
membrane (Millipore, Bedford, MA). Membranes were then
blocked (5% skim milk) and incubated with anti-AH1 Ab at
4°C overnight. After washing, the membranes were incu-
bated in horseradish peroxidase–conjugated sheep anti-
rabbit IgG (Avicenna Research Institute) for 45 minutes. AH1
was detected using an ECL Western blot substrate kit (GE
Healthcare, Uppsala, Sweden) [17].
6. Isolation and pulsing of DCs
DCs were isolated from spleen of BALB/c mice according
to the previously described protocol [18]. Briefly, the spleens
were digested with an enzyme blend containing collagenase
and DNase, and low density mononuclear cells were sepa-
rated using Nycodenz density gradient media. Thereafter,
DCs were purified by magnetic assisted cell sorting using
mouse Pan-DC (Miltenyibiotec, Bergisch-Gladbach, Ger-
many) according to the manufacturer’s instruction. The 
purity of isolated DCs was tested using flow cytometry analy-
sis of CD11c expression and was shown to be more than 90%. 
Splenic DCs were pulsed with a mixture of OVA (Sigma-
Aldrich) (100 µg/mL) and AH1 peptide (10 µg/mL) Ags in
RPMI+10% FBS at 37°C overnight. Non-adherent mature
DCs (DC-Pep-OVA) were then collected and used for injec-
tion of mice. DCs pulsed with AH1 (DC-Pep), those incu-
bated in the absence of AH1 (DC-alone), and DCs loaded
with OVA and P15 (10 µg/mL) were used as controls. 
7. Tumor cell inoculation
CT26 cells were used for tumor induction in mice.
Trypsinized CT26 cells were harvested and washed, and
Table 1. Vaccination protocols for different groups
Group label Tumor induction OVA loading on DC DC inoculation Antigen(s) loaded on DC
Tumor + – – –
DC + – + –
DC-Pep + – + Peptidea)
DC-Pep-OVA + + + Peptide+OVA
DC-P15-OVA + + + P15b)+OVA
OVA, ovalbumin; DC, dendritic cell; Pep, peptide. a)The tumor peptide used in the current study was AH1, b)Peptide derived
from Mycobacterium tuberculosis.
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their density was adjusted to 5!105 cells/100 µL phosphate
buffered saline (PBS). Mice were given subcutaneous injec-
tions into the right flank (100 µL). The day of the inoculation
was considered day 0 in all groups. 
8. Immunization protocols
Tumor-bearing mice were immunized separately with
AH1-pulsed DCs (DC-Pep group) and AH1+OVA-pulsed
DCs (DC-Pep-OVA group) by injection of 6!105 cells/100 µL
PBS into the tumor site. Mice injected with spleen-derived
naive DCs (DC-alone group) or with PBS alone (tumor
group) served as control. To determine whether the observed
responses were specific to the tumor-derived peptide (AH1),
we included another control group: DCs pulsed with OVA
plus P15, as an irrelevant peptide derived from Micobacterium
tuberculosis [12]. Overall, animals were divided into five
groups according to the type of injection they received 
(Table 1). The immunizations were administered on days 3
and 10 following tumor inoculations. In the DC-Pep-OVA
group, we observed no sign of toxicity, including fur loss,
abnormal behavior, signs of allergy or gross abnormalities in
liver, kidney, lung, and gastrointestinal tract. 
9. Tumor volume measurement
To determine the effect of DC vaccination on tumor devel-
opment, local tumor growth was evaluated by measuring
two perpendicular diameters of each tumor using a caliper.
Thereafter, the volume of the subcutaneous tumor was esti-
mated using the following formula: (short diameter)2!long
diameter!0.52. Tumor growth was measured at 3-day inter-
vals for 42 days. On day 42, mice were sacrificed by cervical
dislocation and processed for further analysis.
10. Proliferation assay
Splenocyte proliferation assay was performed using a 
previously described method [19]. Briefly, on day 42 follow-
ing tumor cell inoculation, splenocytes from mice were 
harvested by injection of RPMI-1640 medium into the excised
spleen and crushing through a mesh. Mononuclear cells were
separated by Ficoll density gradient medium. A total of 4!105
splenocytes/mouse from all vaccination groups were plated
in 96-well plates (Greiner, Nürtingen, Germany) containing
Click’s culture medium (Gibco). Cells were incubated at 37°C
and 5% CO2 in the presence of OVA (20 µg/mL), AH1 
peptide (20 µg/mL), or PBS for 72 hours, followed by addi-
tion of 3H-thymidine (1 µCi/mL; GE Healthcare, Stockholm,
Sweden) and incubation for another 18 hours. The cells were 
harvested, transferred onto glass fiber filters (Whatman,
Maidstone, UK), and the level of 3H-thymidyne incorpora-
tion was determined using a scintillation counter (Wallac-
1410, LKB, Ann Arbor, MI). The assay was performed in trip-
licate for each sample.
11. Survival of immunized mice
To determine whether DC immunization of tumor-bearing
mice prolonged their survival, a separate group of animals
underwent the same tumor inoculation and subsequent DC
immunization protocol, as shown in Table 1. The survival of
these mice was monitored at 7-day intervals and the survival
rate was expressed as the percentage of live mice per treat-
ment group.
12. Statistical analysis
Quantitative data from five or seven separate experiments
per each control and test group were analyzed using Graph-
Pad Prism ver. 6.00 for Windows, GraphPad Software
(http://www.graphpad.com; La Jolla, CA), and reported as
mean±standard deviation. The statistical significance of 
differences was determined using Mann-Whitney and/or
Kruskal-Wallis non-parametric tests. Log-rank (Mantel-Cox)
test was used for comparison of the survival curves of vari-
ous vaccination groups. p-values less than 0.05 were consid-
ered statistically significant.
Results
1. Verification of gp70 expression in CT26 cells and tumors
We first generated specific anti-AH1 Ab for assessment of
gp70 expression in CT26 cells. Both hyperimmune serum and
purified Ab exhibited excellent reactivity with the immuniz-
ing peptide as determined by ELISA (data not shown). 
Expression of gp70 protein in CT26 cells was confirmed by
immunofluorescence. As shown in Fig. 1A, anti-AH1 Ab 
reacted positively with CT26 cells, confirming the presence
of gp70. No reactivity was detected in negative controls (Fig.
1B-D). Next, the expression of gp70 protein in CT26 cells and
tumors was confirmed by Western blot analysis using our
polyclonal anti-AH1 Ab. Muscle tissues from BALB/c mice
and 4T1 cells were used as cell negative controls, and rabbit
IgG served as the reagent control. Western blot analysis
clearly identified the presence of two 70-kDa and 90-kDa
protein bands indicative of the presence of gp70 and gp90
(the precursor of gp70 [20]) Ags in both CT26 cells and tumor
lysates. No specific bands were identified in negative 
controls (Fig. 1E). 
Cancer Res Treat. 2015;47(3):518-526
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2. Effect of DC immunotherapy on tumor volume
To determine whether DC treatment had any impact on
tumor growth, the volume of tumors was measured before
and at 3-day intervals after DC vaccination in different treat-
ment groups. In non-vaccinated mice, tumors were visible
on day 9, while in the case of DC-alone and DC-P15-OVA
groups, tumors were measurable with a 3-day delay on day
12. Of particular interest, vaccination with either DC-Pep or
DC-Pep-OVA resulted in delayed onset of visible tumor 
formation, so that no tumor was observed until days 18 and
21 for DC-Pep and DC-Pep-OVA groups, respectively. From
day 18, significantly smaller tumor volume was observed in
mice immunized with DC-Pep or DC-Pep-OVA as compared
to other control groups (p " 0.05) (Fig. 2). In addition, signif-
icantly smaller tumor size was observed in mice receiving
DC-Pep-OVA compared to those injected with DC-Pep on
day 36 and beyond (p " 0.05). The rate of tumor growth 
Fig. 1. Verification of gp70 expression in CT26 cells and tumors. (A-D) Immunofluorescence staining. CT26 cells showed
positive staining with rabbit-anti-mouse AH1 antibody (green cytoplasm). (A) The nuclei were stained using 7-AAD (red).
(B) Murine 4T1 cell line served as the negative cell control. (C) CT26 cells were stained with peptide-adsorbed Ab. (D) CT26
cells were stained with rabbit IgG as the negative reagent control (A-D, !40). (E) Western blot analysis of gp70 expression.
1, CT26 cell lysate; 2 and 5, CT26-derived tumor lysate; 3, murine 4T1 cell lysate (as the negative cell control); 4, normal
murine muscle tissue lysate (as the negative tissue control); 6, CT26 cell lysate treated with rabbit IgG (as the negative reagent
control); 7, CT26 cell-derived tumor lysate treated with rabbit IgG (as the negative reagent control). The 90 kDa band corre-
sponds to gp90, the precursor of gp70.
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followed an increasing trend in all groups. Nonetheless, in
contrast to all other groups, in the DC-Pep-OVA group the
tumor size did not grow with a steep slope (Fig. 2).
3. Splenocyte proliferation response in DC immunized
mice
As a measure of post-immunization proliferation response
to various regimens of Ag loading onto DCs, 3H-thymidine
uptake by splenocytes from different treatment groups upon
in vitro Ag challenge was quantified. Freshly isolated spleno-
cytes from each mouse were stimulated with either AH1
peptide or OVA and proliferation values were determined.
Splenocytes from mice vaccinated with DC-Pep-OVA
showed a significantly more robust proliferation response
compared to other groups (Fig. 3). In particular, in vitro chal-
lenging of the DC-Pep-OVA group with tumor peptide
(AH1) showed a significantly higher proliferation response
than that of the DC-Pep group. In addition, upon stimulation
with AH1, the proliferation rate for the DC-P15-OVA group
was extremely low, so that it was comparable to that of the
negative control groups (i.e., tumor and DC-alone). 
4. Effect of DC immunotherapy on survival rate
To examine the ultimate efficacy of various DC-based 
antitumor treatments, the survival rate of each group was
further evaluated. Post-immunization survival rate in tumor-
bearing mice was presented as the percentage of live mice
per treatment group. The population of mice that were not
immunized at all, mice immunized with naive DCs, and
those injected with DC-P15-OVA showed low survival rates,
so that these mice developed lethal tumors. Importantly, 
immunization of tumor-bearing mice with DC-Pep-OVA 
significantly prolonged their survival in comparison with
mice vaccinated with DC-Pep (p " 0.05) (Fig. 4).
Discussion
Development of efficient methods to cure neoplasm or 
inhibit its progression has long been at the forefront of 
tumor immunologists’ attention. In this regard, targeted 
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immunotherapy using DCs has attracted significant interest.
In particular, numerous studies have attempted to fully 
exploit the potential of potent ex vivo–generated antitumor
DCs in order to elicit efficient T-cell responses [21]. In our
previous study, we showed that the presence of a helper Ag
next to the target Ag during pulsing of DCs could enhance
the proliferation rate of CD8 T cells specific to both the helper
and target Ags, a phenomenon we termed “mutual helper
effect” [12]. In this study, elucidate the in vivo effectiveness
of this approach against tumor, we vaccinated a murine
model of colon cancer with DCs pulsed with the combination
of a helper Ag (OVA) and a tumor Ag (AH1). Readout 
systems including tumor size, survival rate, and tumor 
Ag-specific T-cell proliferation were employed in order to
evaluate the efficacy of DC vaccination. 
The main vaccination group consisted of tumor-bearing
mice vaccinated with DCs loaded with both AH1 and OVA
(DC-Pep-OVA), while the target control group consisted of
tumor-bearing mice inoculated with DC-Pep. Tumor size in
mice treated with DC-Pep-OVA was significantly smaller
compared to that in the DC-Pep group. More importantly, a
significantly higher survival rate was observed in the former
group. In addition, high tumor volumes and mortality rates
in mice treated with DC loaded with OVA plus an irrelevant
peptide (e.g., P15) confirmed the formation of responses 
specific to the tumor Ag, AH1. Together, these results
demonstrated that OVA could function in vivo as a helper Ag
with the ability to augment the efficacy of tumor Ag-loaded
DCs. 
In a somewhat similar study, Casares et al. [13] reported
that protective injection of normal mice with a combination
of an OVA-derived peptide (as the helper Ag) and AH1 (as
the tumor Ag) could induce marked tumor protection
against challenge in a CT26 cell line. However, there are 
several major differences between that study and the current
work: 1) they did not use DCs for immunization and instead
tumor Ag and the helper molecule were injected directly into
mice; 2) they used an OVA-derived peptide instead of the 
intact OVA molecule used in our study; 3) coadministration
of OVA and AH1 was used as a protective rather than the
therapeutic antitumor modality employed in the current
study. Nonetheless, their overall result, similar to our work,
supported the idea that an unrelated but proper Th1 mole-
cule could be used as a helper Ag for eliciting tumor-specific
CTL responses. The potential advantage of our study over
the aforementioned work is that regarding the ability of DCs
to present Ags to CD8 T cells, stronger antitumor responses
could be provoked upon utilization of Ag-loaded DCs rather
than injection of Ags in the absence of DCs [9]. In line with
this assumption, in another section of the above-mentioned
study, Casares et al. [13] used the combination of AH1 and
OVA (again in the absence of DCs) for treatment of tumor-
bearing mice, as a therapeutic rather than a protective 
approach. According to their results, the combination of
OVA and AH1 did not prevent tumor growth. In addition,
based on the results obtained from the same therapeutic 
approach, immunization with AH1 alone had no protective
effect against challenge with CT tumor cells, while here we
showed that, although not significantly, tumor-bearing mice
vaccinated with DC-Pep (AH1) showed better survival than
those treated with DC-alone or not treated at all.
In another section, we obtained splenic cells from tumor-
bearing mice and assessed their proliferative capacity upon
in vitro stimulation with either AH1 or OVA. According to
the results, splenic cells of mice vaccinated with DC-
Pep-OVA showed the highest proliferation rate, which 
further verified the helper role that OVA could play in 
enhancement of AH1-specific immune responses. In our 
previous in vitro study, we showed that injection of DCs
loaded with OVA (helper Ag) plus the target Ag could elicit
secretion of high levels of interferon ! together with robust
proliferative responses of CD8 T cells specific to both Ags
[12]. Eriksson et al. [22], using DCs pre-loaded ex vivo with
cholera toxin (CT)–conjugated tumor Ag, accomplished 
induction of efficient CTL-mediated antitumor responses
both in vitro and in vivo. In that study, CT functioned as both
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compared to those vaccinated with DC-Pep. DC, dendritic
cell; Ag, antigen; OVA, ovalbumin.
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an adjuvant and a helper protein that was able to elicit 
non-specific immune responses and facilitate the uptake and
presentation of the tumor Ag by DCs [22]. Taken together,
these results demonstrate that through utilization of a potent
helper Ag, one might be able to promote robust specific 
immune responses against the Ag of interest (e.g., tumor Ag).
The type of helper Ag and the method used to combine it
with the Ag of interest are among the factors that can influ-
ence the final results of a DC-based antitumor modality. 
Accordingly, in an immunotherapeutic study, it was indi-
cated that utilization of a Th0- or Th2-inducing helper Ag,
would in fact serve the needs of tumor cells, rather than 
prevent tumor growth [13]. In the current study, we did not
determine the type of T cell–mediated responses; however,
as mentioned earlier, in our previous study we observed that
OVA-pulsing of DCs would shift T-cell responses towards
Th1 [12]. In this regard, Eriksson et al. [23], in two DC-based
studies, reported that conjugation of the helper Ag to the 
target Ag could lead to more pronounced antitumor 
responses as compared to simply mixing the Ags [24]. Hence,
as related to the current study, even more potent antitumor
responses might have been achieved upon loading of DCs
with a conjugated form of OVA and AH1 rather than a 
simple mixture of them.
Conclusion
Collectively, our results indicated that co-administration
of OVA (a helper Ag) with AH1 (tumor Ag) to DCs could 
effectively inhibit tumor growth and improve the 
survival rate as well as Ag-specific T-cell proliferation; this 
effect seems more pronounced considering the point that 
simple loading of DC with AH1 alone was less effective.
Nonetheless, as mentioned earlier, administration of one t
herapeutic modality per se would not suffice to overcome the 
multifaceted escape mechanisms utilized by tumor cells. 
Therefore, in our future studies we plan to use the helper Ag 
approach in combination with other related and effective 
modalities such as adenoviral-mediated overexpression of
Th1 cytokines in DCs.
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